SOURCE: digiMedical Solutions, Inc.

July 16, 2008 09:00 ET

digiMedical Solutions, Inc. Continues to Expand Sales in South Florida by Providing .Net-Based Digital Prescription Software and Call Center Services for Dr. Jennifer Bevins

COLLEYVILLE, TX--(Marketwire - July 16, 2008) - digiMedical Solutions, Inc. (PINKSHEETS: DGMS) announced today that the Company has signed a contract with Dr. Jennifer Bevins of Southwest Florida Women's Group, P.A. in Naples, Florida to implement the Company's .Net-based digital prescription handling software, digiRX and digiReauth, and to supply call center services to support the reauthorization of prescriptions. Southwest Women's Group is a multi-physician practice providing obstetrical and gynecological services. Dr. Bevins graduated from the University of Miami in 1999 and completed her residency at Tampa General Hospital. She has been in practice for five years and recently joined the Southwest Florida Women's Group.

Earlier this year, digiMedical announced efforts to expand the Company's sales in Florida by signing contracts with doctors and clinics to implement the Company's proprietary digital prescription software and reauthorization call center services. Since launching those efforts, they have signed contracts with multiple doctors in Florida to include: Drs. Angela Marshall, Wendy Humphrey and Betsy Brothers also of Southwest Florida Women's Group, P.A., Dr. Daniel Kaplan, Dr. Moorthy of Pain Management Center of Naples, Dr. Shardul Nanavati, founder of Advanced Gastroenterology, Drs. Romero, Tineo and Seibert of Oaktree Family Practice, Orthopedic Surgeon Dr. Howard Kapp of Anchor Health Centers, Drs. Santos-Ocampo, Axline and Spilker of the Collier Heart Group, Dr. John Landi, the Medical Director of Vanish Vein and Laser Center and Dr. Wey of the Neuroscience and Spine Associates in Naples, Florida, among others.

digiMedical Prescription Handling Software

digiMedical Solutions has operations in Texas and Florida and has built its own suite of proprietary software to handle prescriptions digitally from the physician's office to the pharmacy, securely and in compliance with all DEA and HIPAA requirements. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and digiAccounting.

Company Fact Sheet and Updates

To be added to digiMedical's corporate e-mail list for shareholders and interested investors or to receive a Fact Sheet on the company, please send an e-mail to ir@digimedical.com.

About digiMedical Solutions, Inc.™

digiMedical Solutions, Inc.™ (www.digimedical.com) is a pharmacy and medical technology company focused on developing next generation digital medical technology with an emphasis on digital prescriptions (d-Prescriptions) that will more closely align the doctor, pharmacist and patient. The company's planned growth will come from three channels: direct marketing of the company's wireless base d-prescription technology to doctors, acquisition of independent pharmacy chains and the sale of certain territories to "market partners" licensed to exploit the digiMedical Solutions™ model. digiMedical Solutions, Inc.™ currently owns and operates five (5) pharmacies located in Texas and Florida. digiMedical Solutions'™ unique business model brings doctor, patients and pharmacies into next generation medical technologies.

Forward-Looking Statement

Statements included in this press release which are not historical in nature, are intended to be, and are hereby identified as "Forward-Looking Statements" for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward Looking Statements may be identified by words including "anticipate," "await," "envision," "foresee," "aim at," "believe," "intends," "estimates" including without limitation, those relating to the company's future business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company's filings with the U.S. Securities and Exchange Commission for additional information and a presentation of the risks and uncertainties that may affect the company's business and results of operations.

Contact Information